mopar, so if PAR faced increased pricing pressure but their sales of FocalinXR didn't decline...does that mean that PAR sold more FocalinXR for far less money?
I really haven't looked hard at the numbers yet...so hopefully you guys can figure out what the hell is going on.
Because at 1st glance...if PAR's monthly revenues didn't drop in Dec/Jan/Feb from FocalinXR sales...then how the hell did IPCI's revenues drop so much???
Did the PAR FocalinXR prescription numbers increase dramatically???
If the prescription numbers didn't increase dramatically and the monthly revenues remained about the same...then IPCI mgmt. definitely owes us a real explanation as to why their revenues from PAR's ongoing FocalinXR sales dropped so drastically in Q1 right!